Xention Acquires Clinical Development Compound

Xention Ltd has announced that it has acquired exclusive rights to develop certain ion channel modulators from Scion Pharmaceuticals, Inc. of Medford, MA.

The compounds were originally developed at Bristol-Myers Squibb (BMS) with whom Xention have entered into a separate agreement under which they will assume and amend the previous license agreement with Scion.

The licensed compounds may be tested to determine efficacy in a number of disorders including overactive bladder (OAB), irritable bowel syndrome and erectile dysfunction.

The most advanced compound has already been subjected to pre-clinical and Phase I clinical development and will be developed further by Xention for the treatment of OAB.

Around 50 million people worldwide suffer from OAB disorders and the market is expected to grow to US$2billion by 2008 in the US alone.

Xention Limited

Xention Limited
Atrial fibrillation drug development

Website
www.xention.com

Downloads

DownloadFull Press Release

Latest News

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.